Ocular Therapeutix disclosed the results of the Week 52 analysis of its SOL‑1 Phase 3 trial for AXPAXLI at the 14th Annual Vit‑Buckle Society meeting on April 13, 2026. The data reinforce the drug’s durability and superiority over the anti‑VEGF comparator.
The primary endpoint, measured at Week 36, showed that 74.1 % of patients receiving AXPAXLI maintained best‑corrected visual acuity versus 55.8 % of those receiving aflibercept (p = 0.0006). At Week 52, the superiority margin widened to 65.9 % versus 44.2 % (p < 0.0001), and visual‑acuity gains were largely preserved through the 52‑week mark.
Anatomical durability was highlighted by central subfield thickness (CSFT) data. The median time to a ≥30 µm increase in CSFT from Week 8 was 39 weeks for AXPAXLI compared with 16 weeks for aflibercept, a 23‑week advantage that underscores the drug’s sustained anatomic control.
Safety data remained favorable, with no treatment‑related ocular serious adverse events reported through Week 52, supporting the tolerability profile of the hydrogel‑based delivery system.
Ocular Therapeutix plans to submit a 505(b)(2) NDA for AXPAXLI based solely on the SOL‑1 data, a strategy that could streamline regulatory review and accelerate market entry.
Financially, the company reported a Q4 2025 net loss of $64.7 million and a 22.4 % decline in revenue versus the same period in 2024. Full‑year 2025 revenue totaled $52.0 million, down 18.5 % from 2024, while the Q1 2025 revenue of $10.7 million fell short of the $16.83 million estimate. The company’s cash balance of $737.1 million provides a runway through 2028, but rising R&D expenses and declining DEXTENZA revenue—driven by reimbursement challenges—continue to pressure profitability.
Executive commentary highlighted the significance of the data: “The new analyses of the SOL‑1 Phase 3 data further strengthen our conviction in AXPAXLI’s potential to redefine retina treatment. A clear drug profile has emerged for AXPAXLI: a product candidate with durability that is unmatched in the wet AMD space while demonstrating excellent sustained disease control.” – Pravin U. Dugel, Executive Chairman, President and CEO. “We are thrilled to report today’s historic data that position AXPAXLI to potentially become one of the most consequential advances in retina. SOL‑1 data provide robust evidence that support AXPAXLI’s potential to deliver safe, durable, and clinically significant visual and anatomic outcomes with a meaningfully reduced treatment burden.” – Pravin U. Dugel. “The data overwhelmingly show we have a drug that has the potential to fundamentally change what is possible in wet AMD treatment. Axpaxli did not just perform well, but it is now the first and only investigational product in wet AMD with a novel mechanism of action to successfully demonstrate superiority to an approved anti‑VEGF agent since their initial approval in wet AMD more than 20 years ago. Many programs have tried to reach this bar. All have failed. Today, Axpaxli succeeded.” – Pravin U. Dugel. “The SOL‑1 data give us great confidence in the SOL‑R non‑inferiority study, which is being conducted in a population likely to be more stable and easier to control than SOL‑1.” – Nadia K. Waheed, Chief Medical Officer.
While the clinical data have been well received, investors remain focused on the company’s financial trajectory. The continued decline in DEXTENZA revenue, coupled with high R&D spending and the need for additional capital to support late‑stage development, has tempered enthusiasm. Nonetheless, the robust efficacy and safety profile of AXPAXLI, combined with a clear regulatory pathway, positions the company for a potentially transformative impact on the wet AMD market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.